NeuraLight Wins 2023 SXSW Innovation Awards

Tel Aviv, Israel & Austin, Texas – March 15, 2023 – NeuraLight, the company digitizing neurological evaluation and care for Parkinson’s, Alzheimer’s, ALS, and Multiple Sclerosis, won the 2023 SXSW Innovation Award in the “Health and MedTech” category, which was announced in a ceremony hosted at the Austin Convention Center on Monday evening.

As part of SXSW, a 10-day celebration of the convergence of tech, film, music, health, and culture in Austin, TX, the SXSW Innovation Awards recognize the most exciting creative developments in the connected world, celebrating the ever-widening variety of technological advancements, achievements and discoveries. NeuraLight won amongst five finalists in its category and was selected from hundreds of companies considered for the award.

“It is an honor to receive the SXSW Innovation Award for Health and MedTech. This recognition affirms our commitment to improving neurological evaluation and care through the advancement of digital biomarkers. We are immensely proud to be among the exceptional group of companies recognized for their world-changing innovations at SXSW. We look forward to continuing to work tirelessly to improve the lives of patients and families impacted by neurological diseases,” said NeuraLight CEO and Co-founder Micha Breakstone, Ph.D.

Pharmaceutical and biotech companies face a significant obstacle in developing treatments for neurodegenerative diseases like Parkinson’s, Alzheimer’s, ALS, and Multiple Sclerosis due to the subjective and highly variable clinical assessments used to evaluate the disorders. NeuraLight has developed a platform that uses advanced deep learning and computer vision algorithms to extract and combine oculometric measures from standard webcam or smartphone videos, providing an objective evaluation of a patient’s neurological health. This technology helps to enable more accurate patient selection and stratification, sensitive disease progression monitoring and aims to help support early diagnosis.

“Creative and transformative ideas are ignited at SXSW. The potential to accurately and sensitively track disease progression and support early diagnosis holds significant promise for transforming the development of drugs for neurodegenerative conditions,” said NeuraLight Chief Innovation Officer Rivka Kreitman, Ph.D. “This award attests to the work that we’re doing at NeuraLight as we continue to advance the clinical evaluation of neurodegenerative diseases.”

The award comes on the heels of a momentous year for NeuraLight. In May 2022, the company raised a $25 million series A to support its goals of providing drug developers with a platform to more effectively measure therapeutic effect, help support an increase in the probability of success for novel neurological therapeutics, and usher in a new era of precision medicine for neurology.

To learn more about NeuraLight, please visit https://neuralight.ai/.

About NeuraLight

NeuraLight is on a mission to transform the lives of billions of people impacted by neurological disorders by digitizing neurological evaluation and care. Its AI-driven platform integrates multiple digital markers to accelerate and improve drug development, monitoring, and precision care for patients with neurological disorders. The technology driving the platform includes proprietary deep learning algorithms which automatically extract a host of digital oculometric markers from facial videos captured with a standard smartphone or webcam, supporting distributed trial design. NeuraLight’s founders are repeat entrepreneurs and industry veterans (including both the co-founder of Chorus.ai and the founding CTO of Flatiron Health) leading a 39-strong team. The company is supported by renowned neurologists and two Nobel laureates as well as a stellar Scientific Advisory Board, and have raised over $30.5M to date.

Contact Information

Madalyn Boyd

Account Coordinator

VSC for NeuraLight

Neuralight@vsc.co